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The orotidine-5-monophosphate decarboxylase (OMPDC) gene, encoding the final enzyme of the de novo
pyrimidine biosynthesis pathway, was deleted using Toxoplasma gondii KU80 knockouts to develop an avirulent
nonreverting pyrimidine auxotroph strain. Additionally, to functionally address the role of the pyrimidine
salvage pathway, the uridine phosphorylase (UP) salvage activity was knocked out and a double knockout of
UP and OMPDC was also constructed. The nonreverting OMPDC, UP, and OMPDC UP knockout
strains were evaluated for pyrimidine auxotrophy, for attenuation of virulence, and for their ability to elicit
potent immunity to reinfection. The UP knockout strain was replication competent and virulent. In contrast,
the OMPDC and OMPDC UP strains were uracil auxotrophs that rapidly lost their viability during
pyrimidine starvation. Replication of the OMPDC strain but not the OMPDC UP strain was also partially
rescued in vitro with uridine or cytidine supplementation. Compared to their hypervirulent parental type I
strain, the OMPDC and OMPDC UP knockout strains exhibited extreme attenuation in murine virulence
(8 logs). Genetic complementation of the OMPDC strain using a functional OMPDC allele restored normal
replication and type I parental strain virulence phenotypes. A single immunization of mice with either the live
critically attenuated OMPDC strain or the OMPDC UP knockout strain effectively induced potent
protective immunity to lethal challenge infection. The avirulent nonreverting OMPDC and OMPDC UP
strains provide new tools for the dissection of the host response to infection and are promising candidates for
safe and effective Th1 vaccine platforms that can be easily genetically engineered.
Toxoplasma gondii is an obligate intracellular protozoan par-
asite that invades and replicates in a wide variety of cell types.
Infections are widespread in humans, and while infections in
healthy individuals are typically asymptomatic, severe disease
can occur in utero or in individuals with severe immune sup-
pression (22, 29, 31). A chronic infection is established and is
characterized by quiescent cysts containing bradyzoites in tis-
sues such as brain, muscle, and eye (42). Chronic infection can
reactivate in AIDS and cause toxoplasmic encephalitis (9, 31)
or recurrent ocular toxoplasmosis, recently recognized as a
prevalent retinal infection in the United States (23, 27). Cur-
rent treatments are poorly tolerated and are ineffective against
chronic stages of infection, and there are no vaccines. Target-
ing of the T. gondii de novo pyrimidine synthesis pathway is one
potential approach to developing more-effective vaccination
strategies based on live attenuated strains with defined genetic
disruptions (14).
The key uracil phosphoribosyltransferase (UPRT) activity in
the pyrimidine salvage pathway can easily be disrupted, and
loss of UPRT has no apparent effect on parasite growth in vitro
or virulence in vivo (4, 8). In the absence of any pyrimidine
salvage pathway, T. gondii still possesses a complete six-step
pathway for the de novo biosynthesis of UMP, the precursor
molecule of all essential pyrimidines (1, 14, 34, 38). Insertional
disruption of the first step of the biosynthetic pathway, en-
coded by the carbamoyl phosphate synthetase II (CPSII) gene,
produced a severe uracil auxotrophy exemplified by the cps1-1
strain of T. gondii, which was incapable of de novo pyrimidine
synthesis (13, 16). After invasion of a host cell, the cps1-1 uracil
auxotrophic mutant was starved for pyrimidines and ceased to
proliferate, since uracil is not readily available for salvage in
mammals (12, 13, 32). The cps1-1 mutant strain also exhibited
an extreme attenuation of virulence in both immune-compe-
tent and severely immune-deficient homozygous gamma inter-
feron (IFN-) knockout mice (13).
Immunization of mice with the live attenuated type I cps1-1
strain elicits a potent CD8 T-cell-dependent lifelong protec-
tive immunity against infection with type I strains (13, 18) and
against infection with type II strains and chronic infection (19).
In contrast, immunization with T. gondii extracts or killed non-
invasive intact parasites does not elicit significant immunity to
reinfection with T. gondii (2, 40). Only actively infected host
cells have been shown to prime CD8 T-cell-dependent im-
munity in T. gondii infection (10, 20, 21).
Immunity is effectively elicited by immunization with the
cps1-1 strain in C57BL/6 (18), BALB/c (13), and tyk2/ sig-
naling-deficient mice (39) and surprisingly also in MyD88/
deficient mice (41). Remarkably, macrophages primed in vivo
by cps1-1 immunization but not naive macrophages also exhibit
extremely efficient ex vivo IFN--mediated innate cellular im-
munity augmenting intracellular rupture and clearance of type
II and type III strains of T. gondii (30, 45–47), whereas virulent
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type I strains resist this cps1-1-induced innate killing mecha-
nism (46).
The lifelong immunity elicited by vaccination with strain
cps1-1 is dependent on CD8 T cells and interleukin 12 (IL-
12) (41, 44) and is also dependent on IFN- (13, 18), although
systemic IFN- is not required for priming (18). Surprisingly,
cps1-1 rapidly elicits functional IL-12p70 both locally and sys-
temically following vaccination (18). In contrast to current
models of viral or intracellular bacterial infections, CD8 T-
cell-intrinsic IL-12 signaling is required for development of
IFN--producing CD8 cytotoxic-T-lymphocyte populations
and for the generation of memory CD8 T cells in response to
cps1-1 (43, 44). Vaccination with cps1-1 induced four distinct
effector CD8 T-cell types based on KLRG1 and CD62L ex-
pression levels (44). The rapidly elicited and abundant popu-
lations of antigen-specific effector CD8 T cells induced by
vaccination with cps1-1 are cytolytic in vitro and in vivo (28).
The nonreplicating cps1-1 vaccine model has significantly ad-
vanced the understanding of the host response, innate immu-
nity, and protective adaptive immunity to T. gondii infection (3,
10, 13, 18, 19, 28, 30, 39, 41, 43–47).
The cps1-1 strain is not easily amenable to further genetic
manipulation, and this strain exhibits an extremely low fre-
quency of reversion to the virulent parental (strain RH) phe-
notype (13). To further address the potential of the six-step
pyrimidine synthesis pathway to develop improved avirulent,
nonreverting, genetically defined, and genetically manipulat-
able strains, we deleted the sixth and final enzyme of the
pathway by targeted disruption of the orotidine-5-monophos-
phate (OMP) decarboxylase, the OMPDC gene, in the RH
strain KU80 knockout background, which now enables highly
efficient gene targeting (17, 24). Targeted disruption of
OMPDC via double-crossover homologous recombination in-
duced severe pyrimidine auxotrophy and resulted in the gen-
eration of nonreverting strains that were essentially completely
attenuated in their virulence in mice. A single immunization
with OMPDC knockout strains effectively induced a potent
protective immunity to subsequent lethal challenge infection
with T. gondii.
MATERIALS AND METHODS
Primers. All oligonucleotide primers used in this study for targeting plasmid
construction and PCR validation of knockout genotypes are given in Table S1
and Table S2 in the supplemental material.
Plasmid constructs. All plasmids were based on the yeast shuttle vector
pRS416, which was employed in a yeast recombinational cloning system (33).
Briefly, recombination to fuse 3 distinct genetic elements (a 5 target flank, a
hypoxanthine-xanthine-guanine phosphoribosyltransferase [HXGPRT] select-
able marker, and a 3 target flank) in their correct order with pRS416 was
performed using 31- to 34-bp crossovers common to pRS416, to the HXGPRT
minicassette, or to gene targeting flanks (see Table S1 in the supplemental
material) as required for yeast recombinational cloning (33). The knockout
targeting plasmids were engineered to delete a small amount of the gene’s
predicted 5 untranslated region (UTR) and essentially the entire predicted
coding region of the targeted genomic locus. Targeting plasmids were verified by
restriction enzyme digest and were then sequenced to verify 100% gene homol-
ogy in targeting DNA flanks.
Plasmid pOMT2-2 was constructed to delete nucleotides 2715149 to 2718446
in the OMPDC locus, defined as TGGT1_010340 (55.m04842) on chromosome
VIIb (chrVIIb) of the toxodb database (www.toxodb.org) (version 5.0). The
HXGPRT minigene cassette (6, 7) was fused between a 1,055-bp 5 genomic
targeting flank and a 994-bp 3 genomic targeting flank amplified from DNA
isolated from the RHku80::HXGPRT strain (17).
Plasmid pOMC2-4 was constructed to remove HXGPRT from the chromo-
somal locus of strain RHku80ompdc::hxgprt (Table 1). Plasmid pOMT2-2 was
digested with PmeI to release the HXGPRT cassette fragment, followed by
self-religation.
Plasmid pNUPT1-1 was designed to delete nucleotides 1108479 to 1111669 of
the uridine phosphorylase (UP) locus on chrXI, annotated as TGGT1_086870.
The HXGPRT minigene cassette was fused between a 1,024-bp 5 targeting
fragment and a 934-bp3 targeting fragment.
Plasmid pGUPROMT was designed to complement uracil auxotrophy and
disrupt UPRT. A chromosomal segment of 3,229 bp corresponding to nucleo-
tides 2714788 to 2718017 on chrVIIb (the OMPDC gene) was flanked with a
1,131-bp 5 UPRT-targeting DNA flank and a 1,119-bp 3 UPRT-targeting DNA
flank. Plasmid pGUPROMT was designed to replace nucleotides 2329098 to
2333188 of the annotated UPRT chromosomal locus, TGGT1_088770.
Strains, culture conditions, and plaque assays. The parental strains of T.
gondii used in this study are RH (37) and the KU80 knockout strains
RHku80::hxgprt and RHku80hxgprt (17). All strains used in this study are
listed in Table 1. Parasites were maintained by serial passage in diploid human
foreskin fibroblasts (HFF) at 35°C (13). PFU assays were performed over 7 days
(36) unless otherwise stated. Uracil, uridine, cytidine, deoxyuridine, deoxycyti-
dine, xanthine, mycophenolic acid (MPA), and 5-fluorodeoxyuridine (FUDR)
were obtained from Sigma Inc., while 6-thioxanthine (6TX) was obtained from
Acros Organics (Thermo Fisher Scientific).
Pyrimidine starvation viability assays. Pyrimidine auxotrophs were inoculated
into two groups of 25-cm2 HFF flasks, where one set of flasks was seeded with
100 to 200 PFU (low dose) and the second set was seeded with 1,000 to 2,000
PFU (high dose). Parasites were allowed to invade for 2 h in uracil medium and
were then rinsed three times with cold phosphate-buffered saline (PBS) to
remove uracil and extracellular parasites. Groups of three flasks from the low-
dose and high-dose groups were then provided with uracil medium to establish
the initial viability (day 0) measured by PFU assay without pyrimidine starvation.
The remaining flasks were then incubated in medium lacking uracil to induce
pyrimidine starvation. At different times (1, 3, or 5 days) after initiation of
pyrimidine starvation, parasites in 3 flasks from the low-dose group and in 3
flasks from the high-dose group were rinsed with cold PBS and then provided
with uracil medium to establish viability as measured by PFU assay. The per-
centage of initial viability remaining after different times of pyrimidine starvation
was determined from PFU counts. PFU data were subjected to a Student t test
and are represented as the means  the standard errors of the means (SEM).
Genomic DNA isolation and PCR. Genomic DNA was purified using a DNA
blood minikit (Qiagen). PCR products were amplified using a 1:1 mixture of Taq
DNA polymerase and Expand Long template PCR (Roche).
TABLE 1. Strains used in this study
Strain Parent Source orreference
RH RH(ERP) 36, 37
RHku80::HXGPRT RHhxgprt 17
RHku80hxgprt RHku80::HXGPRT 17
RHku80ompdc::HXGPRT RHku80hxgprt This study
RHku80up::HXGPRT RHku80hxgprt This study
RHku80ompdchxgprt RHku80ompdc::HXGPRT This study
RHku80ompdcup::HXGPRT RHku80ompdchxgprt This study
RHku80ompdc::HXGPRTuprt::gOMPDC RHku80ompdc::HXGPRT This study
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Transformation of Toxoplasma gondii and knockout verification strategy. Elec-
troporations were performed on the model BTX600 electroporator with 1.33 
107 freshly isolated tachyzoites in the presence of 15 	g of linearized targeting
plasmid DNA as described previously (17). Following selection of parasite
clones, the genotypes of clones were validated in PCR assays to measure the
following: (i) PCR 1, loss of the deleted coding region of the targeted gene (DF
and DR primers); (ii) PCR 2, presence of a target DNA flank (CXF and EXR
primers); (iii) PCR 3, correct targeted 5 integration (CXF and 5DHFRCXR
primers); and (iv) PCR 4, correct targeted 3 integration (3DHFRCXF and
CXR primers) using a previously described strategy (17).
Single and double knockouts at the OMPDC (ompdc) and UP (up) loci.
The RHku80hxgprt strain was transfected with SpeI-linearized pOMT2-2 or
with SpeI-linearized pNUPT1-1, and knockouts were continuously selected in
MPA (25 	g/ml), xanthine (250 	M), and uracil (250 	M) to isolate the cloned
strains RHku80ompdc::hxgprt and RHku80up::hxgprt, respectively. To re-
move the HXGPRT minigene cassette from the RHku80ompdc::hxgprt strain,
parasites were transfected with SpeI-linearized pOMC2-4 and selected in 6TX
(250 	g/ml) and uracil (250 	M). Strain RHku80ompdchxgprt was validated
using PCR 5 with a forward primer (CLOMF) designed in the 3 side of the 5
targeting flank and the CXR primer. The strain was transfected with SpeI-
linearized pNUPT1-1, and the strain RHku80ompdcup::hxgprt was selected
in MPA, xanthine, and uracil medium.
Functional complementation of strain RHku80ompdc::hxgprt. Strain
RHku80ompdc::hxgprt was transfected with the PmeI-linearized plasmid
pGUPROMT, containing the 3,229-bp OMPDC locus. Following transfection,
the culture was maintained in the presence of uracil (250 	M) for 24 h, uracil
medium was removed, and the selection was then continued in the absence of
uracil. Parasites emerging from this selection were subcloned, and individual
isolates were evaluated for their genotype to verify targeted deletion of UPRT
and the simultaneous insertion of a functional allele of OMPDC. The genotype
of the expected gene replacement at the UPRT locus was verified in PCR 1 to
assay for deletion of UPRT, in PCR 6 to assay for correct integration of the
genomic allele of OMPDC (using the primers UPRTCXF and OMXEXR), and
by verifying that individual clonal isolates were also uniformly resistant to 5 	M
FUDR to demonstrate a functional loss of UPRT.
Virulence assays, immunizations, and challenge infections. Adult 6- to
8-week-old C57BL/6 mice and gamma interferon knockout mice, B6.129S7-
Ifngtm1Ts/J (IFN-/), were obtained from Jackson Laboratory (Bar Harbor,
ME) and maintained in Tecniplast seal-safe mouse cages on vent racks at the
Dartmouth-Hitchcock Medical Center (Lebanon, NH, campus) mouse facility.
All mice were cared for and handled according to Animal Care and Use Program
of Dartmouth College using National Institutes of Health approved Institutional
Animal Care and Use Committee guidelines. Groups of 4 mice (C57BL/6) or 3
mice (IFN-/) were injected intraperitoneally (i.p.) with 0.2 ml PBS containing
defined numbers of tachyzoites, and mice were then monitored daily for degree
of illness and survival. Virulence assays were performed twice. C57BL/6 mice
that survived the virulence assay challenge infections were used in subsequent
experiments to determine whether mice were immune to lethal challenge infec-
tions. Surviving immunized mice were infected i.p. with 200 tachyzoites (LD200)
of strain RH 1 month after immunization along with age-matched naive mouse
controls, and mice were then monitored daily to determine the degree of illness
and survival.
RESULTS
Genetic dissection of pyrimidine synthesis and salvage in T.
gondii. To further define the functional role of the de novo
pyrimidine synthesis pathway, we targeted the last step of the
pathway encoded by the OMPDC gene (Fig. 1). Targeting
OMPDC eliminates the possibility that the parasite can access
and salvage any host cell intermediates in the pyrimidine syn-
thesis pathway prior to OMP (Fig. 1). The host cell nucleotides
OMP, UMP, and TMP are inaccessible to the parasite via any
direct salvage pathway (4, 14). We also targeted the UP activity
to functionally address the potential of the pyrimidine salvage
pathway to compensate for defects in the biosynthetic pathway
(Fig. 1). Targeting UP in the salvage pathway eliminates direct
access to host pyrimidine nucleosides (uridine, cytidine, de-
oxyuridine, and deoxycytidine) that can be transported into the
parasite (5). Consequently, phenotypic evaluation of single
knockouts at the OMPDC and UP loci in conjunction with
evaluation of a double knockout (OMPDC and UP) was pre-
dicted to provide a valid test of the current model for pyrim-
idine synthesis and salvage in T. gondii (Fig. 1) (14).
Targeted deletions were constructed in the OMPDC gene
using a strategy (Fig. 2A) based on efficient gene targeting via
double-crossover homologous recombination in strain
RHku80hxgprt (17). The same strategy illustrated in Fig. 2A
was also used to create a targeted disruption of the UP gene.
The disrupted UP strain (RHku80ompdc::HXGPRT) ex-
hibited an intracellular growth rate and plaque forming
ability identical to that of the parental strain,
RHku80::HXGPRT (data not shown). Cloned isolates of
the OMPDC (strain RHku80ompdc::HXGPRT) and UP
(strain RHku80up::HXGPRT) knockouts were verified ge-
notypically using a PCR strategy to demonstrate precisely tar-
geted deletion and insertion of the selectable marker HXG-
PRT at the targeted loci (Fig. 1), (see Materials and Methods;
also data not shown). The OMPDC knockout was then re-
targeted at the disrupted OMPDC locus using the plasmid
pOMC2-2, which, while retaining the same 5 and 3 target
flanks, was deleted for the HXGPRT marker. Transfected
OMPDC knockouts were selected in 6TX to select for tar-
FIG. 1. Model of pyrimidine synthesis and salvage pathways inToxo-
plasma gondii. Top, arrowheads pointing down: the six-step de novo
pyrimidine synthesis pathway results in production of UMP. Molecule
building and intermediate metabolites are shown (PRPP, phosphori-
bosyl-1-pyrophosphate). Biosynthetic enzymes mediating each step of
the pathway are shown in bold. CPSII, carbamoyl phosphate syn-
thetase II; ACT, aspartate transcarbamoylase; DHO, dihydroorotase;
DHODH, dihydroorotate dehydrogenase; OPRT, orotate phosphori-
bosyltransferase; OMPDC, orotidine-5-monophosphate decarboxyl-
ase. Bottom, arrowheads pointing up: the three-step pyrimidine sal-
vage pathway to UMP. Intermediate metabolites are shown. Salvage
enzymes mediating each step of the pathway are shown in bold. UPRT,
uracil phosphoribosyltransferase; UP, uridine phosphorylase; CTD,
cytidine deaminase.
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geted removal of the HXGPRT marker from the disrupted
OMPDC locus (Fig. 2B). Clones resistant to 6TX were isolated,
and the genotype of the OMPDC strain deleted for HXGPRT
(strain RHku80ompdchxgprt) was confirmed by PCR geno-
typing (data not shown). The OMPDC strain deleted for HXG-
PRT was then retargeted using the UP deletion targeting plasmid
pNUPT1-1 to generate the double knockout OMPDC UP
strain (strain RHku80ompdcup::HXGPRT) (Table 1). The
OMPDC and OMPDC UP strains were also evaluated for
their reversion frequency using PFU assays performed in the
absence of uracil supplementation. As expected, no revertants
were detected in multiple independent PFU assays using a total of
1 109 tachyzoites of the OMPDC or OMPDC UP strain
(data not shown).
Functional analysis of pyrimidine synthesis and salvage po-
tential in T. gondii. The precisely targeted and deleted
OMPDC, UP, and OMPDC UP strains were examined
for growth in the absence of uracil supplementation in PFU
assays to illustrate the growth phenotypes. The UP strain and
the parental KU80 knockout strains replicate normally in the
absence and presence of uracil, uridine, or cytidine (data not
shown). In contrast, while the growth rates of the OMPDC
and OMPDC UP strains were normal in uracil, both strains
exhibited a severe pyrimidine auxotrophy and replication de-
ficiency in the absence of uracil supplementation (Fig. 3A and
B). In contrast to the complete rescue of growth and PFU
observed with uracil supplementation, replication of the
OMPDC strain was only partially rescued with high concen-
trations of uridine and was poorly rescued with high concen-
trations of cytidine, as revealed by the markedly decreasing
sizes of the zones of infection present in the PFU (Fig. 3C).
Similar rescue profiles were also observed using deoxyuridine
or deoxycytidine, respectively (data not shown). This pyrimi-
dine rescue profile suggested a differential flux of metabolites
depending on their point of entry into the salvage pathway
FIG. 2. Targeted gene deletion at the OMPDC locus. (A) Strategy
for deletion and validation of the endogenous OMPDC locus via
targeted integration of the HXGPRT marker at the OMPDC locus
of strain RHku80hxgprt. Approximate locations of PCR products
used to validate genotypes are depicted. The parental strain,
RHku80hxgprt, was positive for PCR 1 and PCR 2 products, while
the targeted OMPDC knockout was positive only for PCR 2. In addi-
tion, the OMPDC knockout strain but not the parental strain was also
positive for PCR 3 and PCR 4 products showing correctly targeted
integration of HXGPRT and deletion of OMPDC (see Materials and
Methods). (B) Strategy for cleanup of the deleted OMPDC locus. The
HXGPRT marker was removed from the disrupted OMPDC locus
using the depicted strategy that utilized the ability to negatively select
against the HXGPRT marker using 6TX after transfection with the
pOMC2-4 plasmid. Successfully cleaned-up strains with HXGPRT
deleted were validated using PCR 5 (see Materials and Methods).
FIG. 3. Functional rescue of pyrimidine auxotrophs in Toxo-
plasma gondii. Approximately 200 tachyzoites of strain RHku80
ompdc::HXGPRT (A and C) or strain RHku80ompdc
up::HXGPRT (B and D) were inoculated into a PFU assay in the
absence of pyrimidine supplementation (A and B), in the presence
of uracil supplementation (200 	M) (A and B), in the presence of
uridine supplementation (200 	M) (C and D), or in the presence of
cytidine supplementation (200 	M) (C and D) of the growth me-
dium. The culture monolayer was stained 7 days later to reveal PFU
and HFF monolayers.
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(Fig. 1). Collectively, these results demonstrated that in the
OMPDC background, the parasite-encoded UP provided at
least partial functional rescue of parasite growth of pyrimidine
auxotrophs in vitro through conversion of uridine to uracil or
minor rescue through cytidine that was first converted to uri-
dine by a cytidine deaminase (CTD) activity if extremely high
concentrations of uridine or cytidine, respectively, were exog-
enously supplied in culture medium (Fig. 1).
To definitively demonstrate that the parasite UP acted in the
salvage pathway depicted in Fig. 1 rather than via any potential
alternative pathway to partially rescue pyrimidine auxotrophy
in vitro, we examined the double knockout OMPDC UP
strain in the same PFU rescue assays (Fig. 3D). Growth rescue
was not observed in the OMPDC UP strain using either 200
	M uridine or 200 	M cytidine supplementation or by supple-
menting medium with 4 mM concentrations of uridine or cy-
tidine (data not shown). Replication of the OMPDC UP
strain could be rescued only by uracil supplementation in vitro
(Fig. 3B).
Complementation of pyrimidine auxotrophy. Genotyping of
the OMPDC, UP, and OMPDC UP knockout strains
indicated precise disruption of the targeted loci in the KU80
knockout background. To demonstrate that the knockout
strains had precisely targeted deletions with no unknown pleio-
tropic or epigenetic alterations that could potentially influence
the phenotype(s) under observation, we functionally comple-
mented the pyrimidine auxotrophy. A functional wild-type al-
lele of the OMPDC gene was inserted by targeted gene re-
placement into the UPRT locus, simultaneously deleting the
coding region of the UPRT gene (Fig. 4A). Since the rescue of
pyrimidine auxotrophy in T. gondii is completely dependent on
UPRT (Fig. 1) (14), selection of targeted OMPDC strains is
feasible in the absence of uracil only if functional complemen-
tation is successful. The complemented OMPDC strain
RHku80ompdc::HXGPRTuprt::gOMPDC (Table 1) was
disrupted in UPRT and was resistant to FUDR, and the
growth rate of the complemented strain was normal whether
uracil was absent or present in culture medium (Fig. 4B).
Pyrimidine starvation causes a rapid loss of viability. PFU
assays were used to measure how rapidly pyrimidine auxo-
trophs lost viability intracellularly under conditions of pyrimi-
dine starvation. When subjected to pyrimidine starvation, the
OMPDC UP knockout strain lost viability at a markedly
higher rate than the OMPDC knockout strain (Fig. 5). A
significant loss in viability of the OMPDC UP knockout was
detected as early as 1 day after initiation of pyrimidine starva-
tion. After 5 days of pyrimidine starvation, the viability of the
OMPDC UP knockout strain was reduced to 1.1%  0.6%
of the initial viability, whereas that of the OMPDC knockout
strain was reduced to 38%  1.8% of the initial viability
(Fig. 5).
Pyrimidine biosynthesis is required for virulence. The at-
tenuation of virulence of the nonreverting OMPDC, UP,
and OMPDC UP knockout strains was evaluated. C57BL/6
mice inoculated intraperitoneally (i.p.) with a dose of 20
tachyzoites of the parental strain RHku80::HXGPRT or with
a dose of 20 tachyzoites of the UP strain uniformly suc-
cumbed to virulent infection (Fig. 6A). In contrast, C57BL/6
mice inoculated i.p. with a dose of 1  106, 1  107, or 5  107
tachyzoites of either the OMPDC strain or the OMPDC
UP strain uniformly survived each of these extremely high-
dose parasite challenges (Fig. 6A). Homozygous IFN-/
mice uniformly survived a challenge dose of 1 107 OMPDC
FIG. 4. Complementation of the OMPDC strain. (A) Strategy for
complementation of the OMPDC strain by simultaneous knockout of
UPRT and targeted insertion of the genomic allele of OMPDC at the
UPRT locus. Strain RHku80ompdc::HXGPRT was transfected with
the plasmid pGUPROMT, and parasites that were complemented for de
novo pyrimidine biosynthesis were selected by growth in medium without
uracil supplementation. Approximate locations of PCR 1 (targeted dele-
tion of UPRT) and PCR 6 (targeted integration of the genomic allele of
OMPDC) validation products are shown (see Materials and Methods).
Correctly targeted replacement clones were positive only for the PCR 2
and PCR 6 products and were negative for PCR 1. The parental
strain was positive only for PCR 1 and PCR 2. (B) Functional
rescue of complemented strain RHku80ompdc::HXGPRTuprt::
gOMPDC. Approximately 200 tachyzoites of strain RHku80
ompdc::HXGPRTuprt::gOMPDC were assayed in an 8-day PFU
assay in the absence (no addition) or presence of uracil.
FIG. 5. Pyrimidine starvation causes a rapid loss of parasite viabil-
ity. PFU assays were used to measure how rapidly pyrimidine auxo-
trophs lost viability intracellularly under conditions of pyrimidine star-
vation in a 5-day starvation assay. Viability profiles for the
OMPDCUP knockout strain (solid circles) and the OMPDC
knockout strain (open squares) are shown.
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UP tachyzoites (Fig. 6B). Significantly, extreme virulence was
restored in the complemented uracil auxotroph strain
RHku80ompdc::HXGPRTuprt::gOMPDC (Fig. 6C).
OMPDC and OMPDC UP strains elicit protective im-
munity against virulent T. gondii infection. To examine the
potential of the OMPDC and OMPDC UP strains to serve
as vaccines, C57BL/6 mice that survived the initial challenge
infections with these strains were rechallenged 30 days later
with 200 tachyzoites of strain RH (LD200). All mice vacci-
nated with a single dose of 1  106, 1  107, or 5  107
tachyzoites of the OMPDC strain or the OMPDC UP
strain uniformly survived lethal RH challenge infection (Fig.
6D). In contrast, all naive C57BL/6 mice rapidly succumbed to
the lethal RH challenge infection.
DISCUSSION
Insertional disruption of the first step of the de novo pyrim-
idine synthesis pathway, encoded by the CPSII gene, produced
severe uracil auxotrophic mutants of T. gondii that were inca-
pable of de novo pyrimidine synthesis (13–16). After invasion
of a host cell, the cps1-1 uracil auxotrophic mutant was starved
for pyrimidines and did not replicate. However, the cps1-1
strain is not easily amenable to further genetic manipulation,
and the disruption in CPSII in this strain is insertional rather
than deletional (13). To develop improved nonreverting, avir-
ulent, and well-defined strains that are more easily amenable
to additional defined genetic manipulations, we utilized re-
cently developed KU80 knockout strains (17) to precisely tar-
get and delete the gene encoding the final step of the pyrimi-
dine biosynthetic pathway, the OMPDC activity. We also
examined the functional capacity of the pyrimidine salvage
pathways by deleting the UP salvage activity, which controls
the direct access to host cell pyrimidine nucleosides (26), with
or without an intact pyrimidine biosynthetic pathway. The par-
asite UP activity is nonspecific and is active on uridine, de-
oxyuridine, and thymidine (26).
As predicted from the current model for T. gondii pyrimi-
dine pathways (Fig. 1), disruption of the UP activity had no
effect on parasite growth or virulence. In contrast, disruption
of OMPDC in the OMPDC strain produced a severe uracil
auxotrophy due to the loss of UMP derived from the de novo
pyrimidine synthesis pathway. Rescue of the UMP pool from
the salvage pathway minimally requires parasite UPRT and
pyrimidine supplementation to the growth medium. The
nucleobase uracil provided the most effective functional rescue
of the UMP pool, and uracil supplementation restored a nor-
mal growth rate in the OMPDC strain. The replication of the
OMPDC strain was also partially rescued with high concen-
FIG. 6. Pyrimidine auxotrophs are severely attenuated in virulence
and elicit potent immunity to T. gondii. (A) Groups of C57BL/6 mice
were inoculated i.p. with 20 tachyzoites of strain RHku80::HXGPRT
(solid triangles), 20 tachyzoites of strain RHup::HXGPRT (solid
squares), 1  106, 1  107, or 5  107 tachyzoites of strain
RHku80ompdc::HXGPRT (open squares) (each dose is shown by
the same symbol), or 1  106, 1  107, or 5  107 tachyzoites of strain
RHku80ompdcup::HXGPRT (solid circles) (each dose is shown by
the same symbol). (B) Groups of IFN-/ mice were inoculated i.p.
with 20 tachyzoites of RHku80::HXGPRT (solid triangles) or with
1  107 tachyzoites of strain RHku80ompdcup::HXGPRT (solid
circles). (C) Groups of C57BL/6 mice were inoculated i.p. with 20
tachyzoites of strain RHku80ompdc::HXGPRTuprt::gOMPDC
(solid diamonds) or with 1  107 tachyzoites of RHku80
ompdc::HXGPRT (open squares). (D) Thirty days after i.p. injection
of parasites, all groups of C57/BL6 mice uniformly surviving the
RHku80ompdc::HXGPRT (open squares) and RHku80
ompdcup::HXGPRT (solid circles) inoculations (1  106-, 1  107-,
or 5  107-tachyzoite doses from panel A) were challenged with a
lethal dose of 200 tachyzoites of hypervirulent strain RH. Naive age-
matched mice (open triangles) were given the same lethal challenge.
Mice were monitored over a 30-day period for health and survival.
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trations of uridine and was detectably but poorly rescued with
high concentrations of cytidine. This pyrimidine rescue profile
suggested a differential flux of metabolites depending on their
point of entry into the salvage pathway. Since cytidine must be
first converted to uridine by a CTD activity, this nucleoside
provides reduced rescue compared to that of uridine, and also,
uridine provided reduced rescue compared to that of uracil.
Similar rescue results were observed for deoxyuridine and de-
oxycytidine, respectively, consistent with previous evidence
showing the parasite UP and CTD activities are active on both
the ribonucleoside and the deoxyribonucleoside (11, 25).
T. gondii has no detectable pyrimidine nucleoside kinase
activity (26), and cleavage of nucleosides is due to nucleoside
phosphorylase activities rather than any prominent nucleoside
hydrolase activity (25). Additionally, no detectable pathway to
transport or directly salvage host cell pyrimidine nucleotides
exists (5, 14). Consequently, we conclude that the potential
salvage of host cell uracil and nucleosides (cytidine, deoxycy-
tidine, uridine, and deoxyuridine) is not sufficient to support a
significant rate of parasite replication in mammalian cells in
vitro in pyrimidine auxotroph backgrounds created by disrup-
tion of the OMPDC activity in the biosynthetic pathway.
Our study did not define whether the CTD that converts
cytidine to uridine is a host cell-encoded enzyme or a parasite-
encoded enzyme. The genome of T. gondii predicts a putative
gene locus for a potential CTD gene (TGGT1_051230), and as
mentioned, a CTD activity has been previously found in iso-
lated tachyzoites (25). However, because the enzyme activity
originally reported for the CTD was very low (25), the possi-
bility of host cell contamination of the enzyme preparations
cannot be completely discounted and a genetic approach is still
necessary to conclusively address the functional origin of the
CTD that partially rescues growth of the OMPDC pyrimidine
auxotroph in this study. Rescue of pyrimidine auxotrophy using
exogenously supplied uracil or pyrimidine nucleosides mini-
mally also mechanistically requires parasite plasma membrane
transporters for these pyrimidines, and nucleobase and nucle-
oside transporters have been found in T. gondii (5). Our study
also did not address whether host cell transporters are neces-
sary for salvage of exogenously supplied pyrimidines.
While growth of the OMPDC UP strain was also rescued
completely by uracil supplementation, replication of this dou-
ble knockout was not rescued by supplementation of growth
medium with either uridine or cytidine or their corresponding
deoxyribonucleosides. These results definitively demonstrate
that the salvage of all host cell-derived pyrimidine nucleosides
(cytidine, deoxycytidine, uridine, and deoxyuridine) into the
UMP pool of the parasite is dependent on the sequential
action of the parasite-encoded UP and UPRT activities. These
results suggest that the infected host cell UP activity does not
play any significant role in supporting parasite replication by
providing uracil to the pyrimidine salvage pathway of the in-
tracellular parasite. However, our experiments do not exclude
the possibility that the parasite has limited access to host cell
uracil made available through the activity of the host cell-
encoded UP, but if so, the biochemical flux of this pathway is
not sufficient to support parasite replication.
Previous biochemical and genetic results implicated a poten-
tially significant role of the parasite-specific pathway in salvage
of pyrimidines (4, 13, 14, 25, 35), although it has still been
poorly understood how the biosynthetic and salvage pathways
are integrated and regulated. The ability to now more rapidly
and reliably target gene knockouts and gene replacements in
the KU80 knockout background should accelerate progress in
understanding the pyrimidine pathways, as well as essential
purine salvage and other nutritional pathways critical to intra-
cellular parasite survival and growth (17). Simultaneous
complementation of pyrimidine auxotrophy and targeted dis-
ruption of UPRT (UPRT) with a functional allele of
OMPDC in the OMPDC background now conclusively dem-
onstrate that T. gondii can grow normally with UMP derived
from a fully functional de novo pyrimidine synthesis pathway
while having no functional pyrimidine salvage pathway. Con-
versely, if a OMPDC or OMPDCUP pyrimidine auxo-
troph strain is provided with high levels of the pyrimidine
supplement uracil in growth medium in vitro, the parasite can
also grow normally while deriving UMP from the pyrimidine
salvage pathway in the absence of any functional biosynthetic
pathway.
The absence of UP has no apparent effect on parasite
growth or virulence. However, our assays of viability following
pyrimidine starvation demonstrate that the presence or ab-
sence of UP in pyrimidine auxotrophs is correlated with via-
bility. After 5 days of pyrimidine starvation, the OMPDC
knockout strain retained 38%  1.8% viability while the
OMPDC UP double knockout strain retained only 1.1% 
0.6% viability. Our previous kinetic analysis of pyrimidine star-
vation showed that after 5 days of pyrimidine starvation, the
cps1-1 strain retained 25% viability (13). Collectively, these
observations suggest that the loss of viability of OMPDC
knockouts during pyrimidine starvation is significantly acceler-
ated in the absence of the parasite UP activity.
The essential nature of de novo pyrimidine synthesis, the
extremely limited functional capacities of the pyrimidine sal-
vage pathway in infected host cells in the absence of pyrimidine
supplementation in vitro, and evidence suggesting that uracil is
not readily available in mammals (12, 13, 32) collectively ex-
plain the remarkable attenuation of growth in vitro and atten-
uation of virulence in mice that we observed in the OMPDC
and OMPDC UP strains. The attenuation in virulence of
these nonreverting pyrimidine auxotroph strains approaches
8 logs (or more) compared to the virulent parent RH strain,
where a single viable parasite is lethal to mice (36). The
OMPDC UP strain also exhibits extreme attenuation in
IFN-/ mice, suggesting that the growth disruption in this
background is severe in vivo. Uracil auxotrophy is a profoundly
effective strategy to eliminate virulence in T. gondii infection.
A single immunization of mice with the OMPDC strain or
the OMPDC UP strain elicited a completely protective
immunity to lethal challenge infection. The cps1-1 strain elicits
a potent CD8 T-cell-dependent protective immunity (13, 18,
19, 28, 39, 41) that confers lifelong immunity against infection
with type I strains (13, 18), as well as lifelong immunity against
infection with type II strains and chronic infection (19). The
cps1-1-induced immunity is dependent on IL-12 (18, 41, 44)
and is also dependent on IFN- (13, 18), although systemic
IFN- is not required for priming this immunity (18). This
priming of immunity is characterized by four distinct effector
CD8 T-cell types based on KLRG1 and CD62L expression
levels (44) that produce abundant populations of antigen-spe-
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cific CD8 T cells that are cytolytic in vitro and in vivo (28) and
also elicits effective generation of memory CD8 T cells (43,
44). Recently the CD8 T-cell-dependent immunity elicited by
the attenuated cps1-1 uracil auxotroph strain, which actively
invades the host cell but does not subsequently replicate, was
reported to arise unexpectedly with much faster kinetics than
that observed with replicating strains that actively lyse the
infected cell (28). Surprisingly, the early cytokine response to
the type I uracil auxotroph strain cps1-1 also resembles the
characteristic response of a type II strain in regard to early
production of IL-12 (18). RH challenge parasites are not de-
tected in cps1-1-vaccinated mice by 3 weeks after challenge,
and the genomes of tachyzoites from the original cps1-1 vac-
cination also are not detected at the same time the RH chal-
lenge parasites are assayed (18, 28). While the OMPDC and
OMPDC UP strains elicit an effective protective immune
response against lethal RH challenge, additional experiments
are needed to determine whether long-term immunity is elic-
ited and whether these new strains can be further manipulated
to elicit a protective antigen-based response against other
pathogens in naive mice or in mice already immune to T.
gondii.
Our study provides further evidence that the de novo pyrim-
idine synthesis pathway of T. gondii is essential and that this
pathway provides an excellent target for vaccine design and
chemotherapy. This study defines and validates potentially im-
proved, extremely attenuated, nonreverting, genetically de-
fined, and now genetically manipulatable strains developed in
the KU80 knockout background that enable precise and effi-
cient gene targeting via homologous recombination (17). The
OMPDC and OMPDC UP strains developed in this study
should also provide new tools for the further biological dissec-
tion of innate and adaptive host responses to T. gondii infec-
tion. Significantly, the newly developed nonreverting avirulent
uracil auxotroph strains reported here now potentially provide
an excellent vaccine platform strategy in which to examine
engineered antigens or CD8 T-cell epitopes of interest that
can elicit potent Th1 and other relevant immune responses to
combat significant global infectious diseases that have been
remarkably resistant to previous vaccination strategies.
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